Woodline Partners’s Century Therapeutics IPSC Stock Holding History

Woodline Partners’s Portfolio IPSC Stock Details IPSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.88M	Buy	+3,043,478	New	+$6.4M	0.03%	598
2022 Q3	–	Sell	-208,082	Closed	-$1.75M	–	787
2022 Q2	$1.75M	Hold	208,082	–	–	0.03%	451
2022 Q1	$2.62M	Hold	208,082	–	–	0.04%	342
2021 Q4	$3.3M	Sell	208,082 -42,012	-17%	-$789K	0.05%	343
2021 Q3	$6.29M	Sell	250,094 -31,632	-11%	-$856K	0.1%	225
2021 Q2	$8.27M	Buy	+281,726	New	+$7.15M	0.15%	154

Other funds holding IPSC

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Woodline Partners's IPSC Position: Q1 2026 in Review

Woodline Partners opened a new position in Century Therapeutics (IPSC) in Q1 2026: 3,043,478 shares worth $6.88M. The stake represents 0.03% of the portfolio and ranks #598 among its holdings. This is a return to the name: Woodline Partners previously reported a position in IPSC as recently as Q2 2022.

Woodline Partners first reported a position in IPSC in Q2 2021 and has held it in 6 quarters since. The position peaked at $8.27M in Q2 2021. 72 funds tracked by Wall St. Rank hold IPSC as of Q1 2026.

Woodline Partners held 3,043,478 shares of Century Therapeutics worth $6.88M as of Q1 2026.
Century Therapeutics was a new Woodline Partners position in Q1 2026.
Century Therapeutics made up 0.03% of Woodline Partners's portfolio in Q1 2026, its #598 holding.
Woodline Partners first reported a position in Century Therapeutics in Q2 2021 and has held it in 6 quarters since.
Woodline Partners's Century Therapeutics position peaked at $8.27M in Q2 2021.
72 funds tracked by Wall St. Rank held Century Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.